Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

By afschroeder • March 8, 2026

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. Breast Cancer Res Treat. 2026 Mar 7;216(2):22. doi: 10.1007/s10549-026-07935-3. PMID: 41793559; PMCID: PMC12967648.

Tags: Cyclin-dependent kinase 4/6, Hematology/Oncology, metastatic breast cancer, overall survival, Publications, real-world data, Target trial emulation

Related Posts

A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig[...]

Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study

Ji J, Sun CL, Dale W, Cohen HJ, Kim H, Katheria V, Baclig N, Zektser Y, Niknafs A, Margolis S, Lee C, Smith C, Sedrak[...]

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ,[...]